SCORE risk scale as a prognostic factor after sudden sensorineural hearing loss

Area of Science:

• Otolaryngology
• Cardiology
• Neurology

Background:

• Sudden sensorineural hearing loss (SSNHL) is a complex condition with various potential causes and risk factors.
• Cardiovascular risk factors, including patent foramen ovale (PFO), are increasingly recognized as contributing to SSNHL.
• Current therapeutic strategies involve corticosteroids, but emerging evidence highlights the importance of hyperbaric oxygen therapy (HBOT).

Discussion:

• This study emphasizes the critical role of hyperbaric oxygen therapy (HBOT) as an adjunct treatment for sudden sensorineural hearing loss (SSNHL).
• The application of the Systematic Coronary Risk Evaluation (SCRE) scale is explored for risk stratification in SSNHL patients.
• The potential link between patent foramen ovale (PFO) and SSNHL is investigated, suggesting paradoxical embolism as a possible mechanism.

Key Insights:

• Hyperbaric oxygen therapy (HBOT) should be considered alongside standard corticosteroid treatments for sudden sensorineural hearing loss (SSNHL).
• Early intervention, ideally within 14 days of symptom onset, is crucial for optimal outcomes in SSNHL.
• A high prevalence of patent foramen ovale (PFO) in SSNHL patients suggests a potential association with paradoxical embolism.

Outlook:

• Further research is warranted to elucidate the precise mechanisms linking PFO to SSNHL and to optimize HBOT protocols.
• Integrating cardiovascular risk assessment into the management of SSNHL may improve patient outcomes.
• Developing standardized guidelines for the combined use of HBOT, corticosteroids, and PFO management in SSNHL is essential.